Search

Displaying results 1361 - 1370 of 7538 in total
  1. Drug

    Melphalan flufenamide

    go.drugbank.com/drugs/DB16627
    ApprovedWithdrawn

    [A230123,L32173] Melphalan flufenamide is more readily uptaken by cells than melphalan, and is cleaved to the active metabolite by aminopeptidases. … [A230143,L32173] Melphalan flufenamide was granted FDA approval on 26 February 2021.[L32173].

  2. Drug

    Gepirone

    go.drugbank.com/drugs/DB12184
    Approved

    [A261670,A261675,A182315] Gepirone was approved by the FDA on September 28, 2023, under the brand name EXXUA for the treatment of adults with major depressive disorder. … It was not until an extended-release formulation of gepirone was made available that gepirone became a potential candidate for a new antidepressant.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  3. Drug

    Albiglutide

    go.drugbank.com/drugs/DB09043
    ApprovedInvestigationalWithdrawn

    Albiglutide was approved on April 15, 2014 by the FDA. … It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin.

  4. Drug

    Deflazacort

    go.drugbank.com/drugs/DB11921
    Approved

    [A179446,A179449,L6697] This disease usually manifests by muscle weakness in early childhood followed by loss of the ability to walk (ambulation) as early as age 7. … It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.

  5. Drug

    Aliskiren

    go.drugbank.com/drugs/DB09026
    ApprovedInvestigational

    [A203624] It was developed by Speedel and Novartis and initially approved by the FDA in early 2007. … [L14018] Aliskiren has been proven to efficacious in reducing blood pressure when used alone or in conjunction with other antihypertensive agents.[A203624]

    Categories: Agents Acting on the Renin-Angiotensin System
  6. Drug

    Ancrod

    go.drugbank.com/drugs/DB05099
    ApprovedWithdrawn

    Currently, Viprinex®/ancrod is not approved or marketed in any country, but is being investigated as a stroke treatment in worldwide clinical trials. In January 2005, the U.S. … and oxygen to portions of the brain, for which phase III trials are currently being conducted.

  7. Drug

    Silicon dioxide

    go.drugbank.com/drugs/DB11132
    Approved

    Inhalation of fine crystals is toxic to humans leading to respiratory toxicity. In powdered food products and pharmaceutical tablets, silicon dioxide is added as a flow agent to absorb water.

    Mixtures: NAVI MAXON Sirin Doctor, Alegria Neo
  8. Drug

    Mazindol

    go.drugbank.com/drugs/DB00579
    Approved

    Mazindol is a tricyclic anorexigenic agent that is unrelated to and less toxic than [amphetamine], but with some similar side effects. … It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  9. Drug

    Butyrfentanyl

    go.drugbank.com/drugs/DB09173
    ExperimentalIllicit

    [L7811] Butyrfentanyl has no current legitimate clinical applications, but anecdotal reports indicate it may occasionally be surfacing on the grey-market as a recreational drug. … [L7811] Butyrfentanyl was first synthesized in 1961 by Janssen Pharmaceuticals as a new opioid analgesic.

  10. Drug

    Niraparib

    go.drugbank.com/drugs/DB11793
    ApprovedInvestigational

    [L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health Canada on June 27, 2019. … [A253248] First approved by the FDA on March 27, 2017,[A253912] niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer.